Risk factors for grade 3/4 transaminase elevation in patients with chronic lymphocytic leukemia treated with idelalisib

Affiliations

• ¹ Dana-Farber Cancer Institute/Harvard Cancer Center, Boston, MA, USA. Jennifer_Brown@dfci.harvard.edu.
• ² Memorial Sloan Kettering Cancer Center, New York, NY, USA.
• ³ Weill Cornell Medical College, New York, NY, USA.
• ⁴ Herbert Irving Comprehensive Cancer Center (New York-Presbyterian Columbia University Medical Center), New York, NY, USA.
• ⁵ Center for Chronic Lymphocytic Leukemia, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
• ⁶ Hematology Department, Niguarda Cancer Center, Milan, Italy.
• ⁷ Chao Family Comprehensive Cancer Center at UC Irvine Medical Center, Orange, CA, USA.
• ⁸ Gilead Sciences, Inc, Foster City, CA, USA.
• ⁹ Medical University of Lodz, Lodz, Poland.
• ¹⁰ Experimental Haematology, University of Leeds, Leeds, UK.